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Background/aim: Familial Mediterranean fever (FMF) is a disease that is mainly diagnosed with clinical features. Several wellknown inflammatory markers increase in FMF. However, there is still a need for diagnostic tests for specifying FMF and monitoring
inflammatory activity. CXCL16 is a chemokine produced by inflammatory cells that demonstrate efficacy in the acute phase response.
In this study, we aimed to investigate the relationship between CXCL16 levels and FMF disease and to evaluate CXCL16 levels as a novel
biomarker for FMF.
Materials and methods: Fifty-three male patients diagnosed with FMF and sixty healthy individuals were included in this crosssectional study. Blood samples were taken in the first 24 h of the attack periods. Serum soluble CXCL16 was evaluated by enzyme-linked
immunosorbent assay (ELISA) method.
Results: CXCL16 (P < 0.001), erythrocyte sedimentation rate (P < 0.001), C-reactive protein (P < 0.001), and fibrinogen (P = 0.005)
were significantly higher in FMF group than in control group. Receiver operating characteristic (ROC) curve analysis revealed a cut
off value of CXCL16 as 2.68 ng/ml with 83% sensitivity and 68% specificity (P < 0.001). Logistic regression analysis indicated that high
CXCL16 and erythrocyte sedimentation rate levels were predictive parameters for FMF disease (OR 8.31; 95% CI 2.59-26.62; p <0.001)
(OR 1.27; 95% CI 1.12-1.44; P < 0.001). There was no correlation between CXCL16 levels and attack frequency and disease duration (P
= 0.395, P = 0.956).
Conclusion: To the best of our knowledge, this is the first study evaluating serum soluble CXCL16 levels as a biomarker for FMF.
CXCL16 levels were significantly higher and were predictive for monitoring inflammatory activity in patients with FMF. CXCL16 may
be a promising biomarker for FMF diagnosis.
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1. Introduction
Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease characterized by recurrent fever and
pain episodes mainly secondary to polyserositis, e.g., in
the peritoneum, pleura, or joints. Although FMF has a distinct ethnic distribution, patients have been reported from
many countries in the world. FMF is commonly detected
in Sephardic Jews, Armenians, Turks, Greeks, Arabs, and
Italians in the Mediterranean region [1,2]. FMF is a genetic disease resulting from MEFV gene variations [2,3]. This
gene forms the protein of pyrin, which plays an important
role in inflammation and apoptosis [2–4]. However, exact
mechanism of pyrin pathway is not clear yet. One speculation for MEFV mutation is that pyrin and antiinflammatory protein production decreases and inflammatory

conditions cannot be suppressed, thereby resulting in fever
and inflammation in certain areas of the body.
There is currently no definitive diagnosis of FMF and
it is diagnosed by clinical findings according to the Tel
Hashomer criteria [1–5]. Ethnicity, family history, and the
mutation in MEFV (Mediterranean fever) gene supports
the diagnosis in patients with clinical findings although it
is not a requirement. Other findings that contribute to the
diagnosis are the high blood levels of acute phase reactants
during attack periods of FMF. The major mechanism of
pathogenesis for clinical manifestations includes overactivation of cytokine cascades [3,5]. Abnormal pyrin protein,
which is proposed as a result of MEFV gene mutations,
was presented to precipitate ineffective suppression of inflammation and was responsible for the inflammatory process [3].
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Difficulties lead to delays in diagnosis of FMF. The main
problems are atypical clinical presentations, which do not
fully meet the diagnostic criteria and overlap diseases
[6]. Considering that the average delay in diagnosis of
FMF is 7.3 years; one can speculate that new, reliable, fast
parameters are required for FMF diagnosis [7].
CXCL16 is a chemokine produced by inflammatory
cells which are a member of the chemotactic cytokine
superfamily and have an important role in inflammatory
processes such as rheumatoid arthritis, inflammatory
bowel disease, SLE, Behçet’s disease, and gout disease,
as well as tissue damage and fibrosis [8–13]. CXCL16
activates CXC motif-receptor 6, which is synthesized
in several cells, especially leukocytes [14]. Unlike the
common chemokines, CXCL16 is expressed in two forms;
on the surface as transmembrane protein and soluble
CXCL16. sCXCL16 increases the migration of CXCR6 +
cells (e.g. CD8 + T cells, CD4 + T cells, NK cells, plasma
cells, monocytes) to secondary lymphoid organs and
inflammation sites [15,16]. Thus, an inflammatory cascade
is initiated via sCXCL16.
In this study, our aim was to investigate the serum
CXCL16 levels of patients in the FMF attack compared to
healthy individuals and to investigate the role of CXCL16
on the diagnosis and activity of FMF disease.
2. Materials and methods
2.1. Study population
Fifty-three male patients diagnosed with FMF and sixty
healthy age-matched male individuals were enrolled
in this cross-sectional study. Local ethics committee
approved the study. Informed consents were obtained
from all participants.
The FMF attack period was diagnosed by Tel Hashomer
criteria and combining high levels of acute phase reactants
(APR) with positive physical examination. All patients had
peritonitis in terms of phenotype characteristics.
All findings of the patients were recorded for further
evaluation and classification. Blood samples were obtained,
and physical examination was performed to the patients
who referred with FMF attack.
We performed a strict exclusion criteria. Patients
using nonsteroidal antiinflammatory drugs, steroids,
immunosuppressants, or immune regulatory drugs, and
patients with cardiovascular disease, acute or chronic liver,
or kidney disease, chronic obstructive pulmonary disease,
rheumatological disease, malignancy, thyroid disease,
immune deficiency, hypertension, diabetes mellitus, acute/
chronic infection, bleeding disease, and those who did
not meet the study criteria were excluded from the study.
Blood samples were obtained in the first 24 h of the attack
period.
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2.2. CXCL16 measurements
Blood samples were centrifuged at 5000 rpm for 5 min
and 2 cc serum was separated into eppendorf tubes for
CXCL16 tests and stored at –80°C. After a sufficient
sample size was reached, all samples were tested in the
biochemistry laboratory. CXCL16 was analyzed by ELISA
(Human CXCL 16 Immunoassay ELISA Kit, R&D Systems
Inc Minneapolis, USA) according to the manufacturer’s
recommendations.
2.3. Statistical analysis
SPSS 20.0 (IBM Corp., Armonk, NY, USA) was used for
statistical analysis. Descriptive statistics were performed
and Kolmogorov–Smirnov test was used to check the data
for normal distribution. Comparisons of the groups were
made by student T test for the data with normal distribution,
and Mann–Whitney U test for the data without normal
distribution. Categorical data were assessed by Chi-square
test. Receiver operating characteristic (ROC) analysis
was used to evaluate the sensitivity and specificity of
CXCL16 in FMF patients. Logistic regression analysis was
performed to determine the parameters predicting FMF
attack. Pearson and Spearman analyses were used for the
correlation analysis. The P value <0.05 was considered
statistically significant.
3. Results
Demographic and clinical data of patient groups are
presented in Table 1. CXCL16 (P < 0.001), CRP (P <
0.001), fibrinogen (P = 0.005), and ESR (P < 0.001) were
significantly higher in the FMF group compared to the
control group, while BMI (P = 0.011) was higher in healthy
individuals.
ROC curve analysis revealed a cut off value of CXCL16
as 2.68 ng/mL with 83% sensitivity and 68% specificity
(P < 0.001) (Table 2, Figure). Logistic regression analysis
indicated that high CXCL16 and sedimentation levels were
predictive parameters for FMF disease (OR 8.31; 95% CI
2.59–26.62; P < 0.001) (OR 1.27; 95% CI 1.12–1.44; P
< 0.001) (Table 3). There was no correlation between
CXCL16 levels and annual attack frequency and disease
duration of FMF patients (P = 0.395, P = 0.956).
4. Discussion
To the best of our knowledge, this is the first study
evaluating serum soluble CXCL16 levels as a biomarker
for FMF. In this study, we showed that patients with FMF
attacks had higher serum CXCL16 levels compared to
healthy individuals and CXCL16 had a predictive role in
the diagnosis of FMF disease.
Higher ESR, CRP, fibrinogen, white blood cell count,
and serum amyloid A (SAA) are expected results in
FMF disease compared to the attack-free period [17,18].
However, in a systematic review investigating acute phase
reactants used for FMF diagnosis, Erer et al. reported that

AKYOL et al. / Turk J Med Sci
Table 1. Demographic and clinical characteristics of patients
with FMF and healthy controls.

Group
Age, years
BMI, kg/m2
Smoking, n %
Disease duration,
years
Attack frequency,
per year
WBC, 10³/μL

Healthy
FMF patients (n
controls (n
= 53)
= 60)
24.1 ± 3.4
27.2 ± 6.7
23.0 ± 3.5
28/53. 52.8%

24.6 ± 2.8
27/60. 45%

P value
0.090
0.011*
0.370

12.6 ± 5.9
2.6 ± 0.9
7.291 ± 2.225

CRP, mg/L

10.5 ± 11.1

ESR, mm/h

19.2± 15.4

Fibrinogen, mg/dL

298.6 ± 94.9

Glucose, mg/dL
LDL-Cholesterol,
mg/dL
Triglyceride, mg/
dL
CXCL 16, ng/mL

82.9 ± 8.3

6.851 ±
1.400
5.1 ± 12.5
4.8 ± 3.4
236.4 ±
52.2
84.2 ± 8.1

89 ± 29.3
115.1 ± 56.5
3.20 ± 0.62

94.9 ± 26.5
105.3 ±
57.9
2.57 ± 0.38

0.236
<0.001*
<0.001*
0.005*
0.412
0.299
0.239
<0.001*

BMI body-mass index, WBC white blood cell,ESR erythrocyte
sedimentation rate, CRP C reactive protein, CXCL16 serum CXC
chemokine ligand 16.
*P < 0.05 was considered statistically significant.

there was no effective acute phase reactant to diagnose
FMF disease [18].
Actually, maybe as one of the limitations in our study, we
could not test the SAA between these parameters because
SAA was not among our routine tests in our biochemistry
lab. Nevertheless, Çakan et al. recently reported that SAA
is a sensitive but nonspecific marker to show inflammation
in FMF [19]. The authors demonstrated that SAA levels
increase significantly in febrile upper respiratory infections
[19].
Innate immune system in FMF patients is proposed
to be disrupted and the disease progresses with episodes
of systemic inflammation [20]. Innate immune system

activates the adaptive immune system by antigen
presenting cells. Thus, B and T cells respond and result
as disease symptoms [20]. IL-1β, IL-1α, TNF α, TNF β
and IL-6 play an important role in these mechanisms [5].
CXCL16 has been reported to play an activating role in
the pathophysiology of these inflammatory cascades [14].
In addition, Funk T et al. noted that dendritic cells have
critical roles in FMF pathogenesis and disease activation
[21]. CXCL16 is also known to be expressed in dentritic
cells and is effective in triggering inflammation [14].
Inflammatory cytokines, such as TNF α and interferongamma, which play an important role in the pathogenesis
of FMF, have also been shown to increase CXCL16
production [22]. In the light of these mechanisms, our
findings suggest that high CXCL16 levels can be a relevant
diagnostic marker for FMF disease.
Literature states an increase of CXCL16 in several
inflammatory diseases [8–13,16]. In our study, logistic
regression analysis indicated that high CXCL16 and ESR
levels were predictive parameters for FMF disease. We
think that the major advantage of CXCL16 over common
widely available conventional APRs would be its OR of 8.31
for predicting FMF while ESR’s OR was 1.27. In addition
to that, ROC curve analysis revealed satisfactory scores of
sensitivity and specificity for CXCL16. Eventually, there is
need for further prospective studies to evaluate CXCL16 in
different periods of FMF disease and its role at differential
diagnosis.
As an interesting result of our study, there was not any
correlation between CXCL16 levels and attack frequency
and disease duration of FMF patients. This result may
indicate that CXCL16 is effective especially in attack
period of FMF pathogenesis. On the other hand, colchicine
treatment can cause this result as it has antiinflammatory
effects and can cause a decrease in proinflammatory
cytokine levels [2–4]. Another reason may be the crosssectional design of the study that the samples reflect only
one time period.
Another finding in our study was that BMI (body mass
index) values were significantly higher in control group
than in FMF patients. A relationship has been proposed
between obesity and CXCL16 [23]. In this regard, Lopes et
al. reported that the overweight increases CXCL16 levels in
young adults (18–30 years old) [23]. We consider that this
finding of BMI values, which were significantly lower in

Table 2. Receiver operating characteristic (ROC) analysis of CXCL16 in patients with FMF.

CXCL16

AUC (95%)

Cut off value

p

0.820 (0.739–0.900)

2.68 ng/mL

<0.001*

Sensitivity (%)

Specificity (%)

83

68

AUC area under the curve; CXCL16 serum CXC chemokine ligand 16,
* P < 0,05 was considered statistically significant.
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Figure. Reciever operating characteristic (ROC) curve of CXCL16 in patients with FMF.

Table 3. Logistic regression analysis of parameters associated
with FMF.
Variable
CXCL16 (>
cut-off value
2,68 ng/mL)
ESR, mm/h

Odds ratio

95 % confidence
interval

P value

8.31

2.59–26.62

<0.001*

1.27

1.12–1.44

<0.001*

CXCL16 serum CXC chemokine ligand 16; ESR erythrocyte
sedimentation rate
* P < 0,05 was considered statistically significant.

patients with FMF than healthy controls, may consolidate
the diagnostic value of CXCL16 in patients with FMF.
There are other new candidate biomarkers for FMF in
the literature [17,24–31]. Pentraxin-3, omentin, fetuin,
calprotectin, serum amyloid A, CD144+, and CD146+
as circulating endothelial microparticles, endocan,
chitotriosidase, serum matrix metalloproteinase-9 and
tissue inhibitor of metalloproteinase-1, S10012A and
resolvin D1 has been investigated and had promising
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results. However, there is still need for prospective large
cohort studies to use these novel biomarkers in daily
practice. This study has some limitations. First, the study
population was small. Second, all study participants were
male because the study was conducted at a tertiary military
center. However, we anticipate that this limitation will not
weaken our results due to the efficient homogenization
between the groups. Third, CXCL was only determined
during attack period and was not analyzed in between
attacks. On the other hand, our study population is young
and they have no comorbid situations. Thus our strict
exclusion criteria render our research valuable.
In conclusion, we showed that CXCL16 levels were
significantly higher in patients with FMF than in healthy
individuals. Serum soluble CXCL16 levels may be a novel
biomarker for FMF disease. Prospective, randomized,
large studies are needed for elucidating the role of CXCL16
in the pathogenesis of FMF.
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